DWA
DCOY

Douglass Winthrop Advisors’s Decoy Therapeutics DCOY Stock Holding History

Douglass Winthrop Advisors’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2
Closed -$117K – 280
2021
Q1 		$117K Hold
2
– – ﹤0.01% 264
2020
Q4 		$72K Hold
2
– – ﹤0.01% 263
2020
Q3 		$67K Hold
2
– – ﹤0.01% 264
2020
Q2 		$104K Hold
2
– – ﹤0.01% 232
2020
Q1 		$54K Hold
2
– – ﹤0.01% 229
2019
Q4 		$298K Hold
2
– – 0.01% 230
2019
Q3 		$429K Buy
+2
New +$682K 0.02% 192

Other funds holding DCOY

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Douglass Winthrop Advisors's DCOY Position: Q2 2021 in Review

Douglass Winthrop Advisors sold out of Decoy Therapeutics (DCOY) in Q2 2021, closing a stake of 2 shares — an estimated $117K sold.

Douglass Winthrop Advisors first reported a position in DCOY in Q3 2019 and held it in 7 quarters. The position peaked at $429K in Q3 2019. 27 funds tracked by Wall St. Rank hold DCOY as of Q2 2021.

  • Douglass Winthrop Advisors reported no remaining Decoy Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Douglass Winthrop Advisors sold 2 Decoy Therapeutics shares in Q2 2021, an estimated $117K.
  • Douglass Winthrop Advisors first reported a position in Decoy Therapeutics in Q3 2019 and held it in 7 quarters.
  • Douglass Winthrop Advisors's Decoy Therapeutics position peaked at $429K in Q3 2019.
  • 27 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q2 2021.

Based on Douglass Winthrop Advisors's 13F filing for Q2 2021, filed 2 Aug 2021.